Published in Immunology on April 01, 1966
Receptors on immunocompetent cells. II. Specificity and nature of receptors on dinitrophenylated guinea pig albumin- 125 I-binding lymphocytes of normal guinea pigs. J Exp Med (1971) 2.92
Antihapten antibody specificity and L chain type. J Exp Med (1967) 2.33
Phylogen of immunoglobulin structure and function. 3. Immunoglobulins of the chicken. J Exp Med (1969) 2.19
Presence of two types of L polypeptide chains in guinea pig 7S immunoglobulins. J Exp Med (1966) 1.43
Studies on cell-free synthesis of rat immunoglobulins, II. Synthesis of immunoglobulin and of antibody to the dinitrophenyl hapten. Proc Natl Acad Sci U S A (1967) 1.32
Quantitative variations in L chain types in guinea pig antihapten antibodies. J Exp Med (1966) 1.05
Conformational change and complementarity in the combination of H and L chains of immunoglobulin-G. Proc Natl Acad Sci U S A (1967) 0.93
Antigen recognition. IV. Discrimination by antigen-binding immunocompetent B cells between immunity and tolerance is determined by adherent cells. J Exp Med (1976) 0.81
Separation of univalent fragments from the bivalent rabbit antibody molecule by reduction of disulfide bonds. Arch Biochem Biophys (1960) 13.40
Reduction of gamma-globulins. Arch Biochem Biophys (1962) 13.22
DITHIOTHREITOL, A NEW PROTECTIVE REAGENT FOR SH GROUPS. Biochemistry (1964) 10.04
Studies on structural units of the gamma-globulins. J Exp Med (1961) 8.20
THE ARRANGEMENT OF THE PEPTIDE CHAINS IN GAMMA-GLOBULIN. Biochem J (1963) 7.40
Properties of guinea pig 7S antibodies. I. Electrophoretic separation of two types of guinea pig 7S antibodies. J Exp Med (1963) 6.39
The preparation and some properties of purified antibody specific for the 2,4-dinitrophenyl group. J Exp Med (1960) 5.58
A model for the myosin molecule. Biochim Biophys Acta (1960) 4.40
STRUCTURE AND BIOLOGICAL ACTIVITY OF IMMUNOGLOBULINS. Adv Immunol (1964) 4.21
EQUILIBRIUM DIALYSIS FOR MEASUREMENT OF ANTIBODY-HAPTEN AFFINITIES. Methods Med Res (1964) 2.45
The affinity of the reticulo-endothelial system for various modified serum proteins. Br J Exp Pathol (1960) 1.90
THE SUBUNITS OF PURIFIED RABBIT ANTIBODY. Biochemistry (1964) 1.77
STUDIES ON THE PROPERTIES OF FRAGMENTS OF GUINEA PIG GAMMA-1 AND GAMMA-2 ANTIBODIES OBTAINED BY PAPAIN DIGESTION AND MILD REDUCTION. J Immunol (1964) 1.74
BINDING CAPACITY OF REDUCTIVELY FRAGMENTED ANTIBODIES TO THE 2,4-DINITROPHENYL GROUP. Science (1963) 1.73
POLYPEPTIDE CHAINS OF RABBIT GAMMAGLOBULIN. Science (1963) 1.52
Histocompatibility-linked immune response genes. Science (1972) 16.79
A population of lymphocytes bearing a membrane receptor for antigen-antibody-complement complexes. I. Separation and characterization. J Exp Med (1970) 15.86
Receptors for complement of leukocytes. J Exp Med (1968) 11.57
The regulatory influence of activated T cells on B cell responses to antigen. Adv Immunol (1972) 9.43
Genetic control of specific immune responses. Adv Immunol (1969) 8.81
Properties of antibodies cytophilic for macrophages. J Exp Med (1966) 8.64
Binding of sheep red blood cells to a large population of human lymphocytes. Nature (1971) 7.67
Cell interactions between histoincompatible T and B lymphocytes. VII. Cooperative responses between lymphocytes are controlled by genes in the I region of the H-2 complex. J Exp Med (1975) 7.64
The role of membrane receptors for C3b and C3d in phagocytosis. J Exp Med (1977) 6.19
Phagocytosis of immune complexes by macrophages. Different roles of the macrophage receptor sites for complement (C3) and for immunoglobulin (IgG). J Exp Med (1972) 6.13
Cell selection by antigen in the immune response. Adv Immunol (1969) 6.05
Gamma interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites. Nature (1988) 5.99
The function and interrelationships of T-cell receptors, Ir genes and other histocompatibility gene products. Transplant Rev (1975) 5.88
Carrier function in anti-hapten immune responses. I. Enhancement of primary and secondary anti-hapten antibody responses by carrier preimmunization. J Exp Med (1970) 5.71
Genetic control of immune responses in vitro. V. Stimulation of suppressor T cells in nonresponder mice by the terpolymer L-glutamic acid 60-L-alanine 30-L-tyrosine 10 (GAT). J Exp Med (1974) 5.55
Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med (1984) 5.47
A hypothesis to relate the specificity of T lymphocytes and the activity of I region-specific Ir genes in macrophages and B lymphocytes. J Immunol (1978) 5.07
Enhanced binding of neuraminidase-treated sheep erythrocytes to human T lymphocytes. Blood (1973) 4.99
Complement receptor (CR1) deficiency in erythrocytes from patients with systemic lupus erythematosus. J Exp Med (1982) 4.96
Role of MHC gene products in immune regulation. Science (1981) 4.84
Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection. J Exp Med (1980) 4.81
TRAP is necessary for gliding motility and infectivity of plasmodium sporozoites. Cell (1997) 4.65
The behavior of hapten-poly-L-lysine conjugates as complete antigens in genetic responder and as haptens in nonresponder guinea pigs. J Exp Med (1966) 4.58
Functional specificity of thymus- dependent lymphocytes. Science (1977) 4.31
Carrier function in anti-hapten antibody responses. 3. Stimulation of antibody synthesis and facilitation of hapten-specific secondary antibody responses by graft-versus-host reactions. J Exp Med (1971) 4.29
Cell interactions between histoincompatible T and B lymphocytes. The H-2 gene complex determines successful physiologic lymphocyte interactions. Proc Natl Acad Sci U S A (1973) 4.12
Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. Nature (1989) 4.08
Cell interactions between histoincompatible T and B lymphocytes. IV. Involvement of the immune response (Ir) gene in the control of lymphocyte interactions in responses controlled by the gene. J Exp Med (1973) 4.05
A new complement function: solubilization of antigen-antibody aggregates. Proc Natl Acad Sci U S A (1975) 3.97
Improved complementation in the cytotoxic test. Transplantation (1970) 3.93
Migration of Plasmodium sporozoites through cells before infection. Science (2001) 3.89
A single major pathway of T-lymphocyte interactions in antigen-specific immune suppression. Scand J Immunol (1981) 3.85
Hybridoma produces protective antibodies directed against the sporozoite stage of malaria parasite. Science (1980) 3.71
Ca++-dependent binding of antigen-19 S antibody complexes to macrophages. J Immunol (1969) 3.70
Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). Selective modification of a complement regulatory protein. J Exp Med (1986) 3.68
Studies on the mechanism of solubilization of immune precipitates by serum. J Exp Med (1976) 3.68
Complement receptor is an inhibitor of the complement cascade. J Exp Med (1981) 3.65
Immunosuppressive factor(s) extracted from lymphoid cells of nonresponder mice primed with L-glutamic acid60-L-alanine30-L-tyrosine10 (GAT). J Immunol (1976) 3.64
Cloning of decay-accelerating factor suggests novel use of splicing to generate two proteins. Nature (1987) 3.62
The immune response genes of the major histocompatibility complex. Immunol Rev (1978) 3.61
The effect of the amount of mycobacterial adjuvants on the immune response of strain 2, strain 13 and Hartley strain guinea pigs to DNP-PLL and DNP-GL. J Immunol (1969) 3.53
Unique role of the complement receptor CR1 in the degradation of C3b associated with immune complexes. J Exp Med (1982) 3.42
Organ and isotype distribution of plasma cells producing specific antibody after oral immunization: evidence for a generalized secretory immune system. J Immunol (1979) 3.37
Antigen presentation by hapten-specific B lymphocytes. I. Role of surface immunoglobulin receptors. J Exp Med (1984) 3.36
Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria. J Exp Med (1985) 3.33
Inhibition of development of exoerythrocytic forms of malaria parasites by gamma-interferon. Science (1986) 3.33
Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc Natl Acad Sci U S A (1993) 3.27
Circumsporozoite proteins of human malaria parasites Plasmodium falciparum and Plasmodium vivax. J Exp Med (1982) 3.26
Cell surface immunoglobulin. XI. The appearance of an IgD-like molecule on murine lymphoid cells during ontogeny. J Exp Med (1975) 3.26
Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria. Science (1985) 3.24
Antigen- and receptor-driven regulatory mechanisms. IV. Idiotype-bearing I-J+ suppressor T cell factors induce second-order suppressor T cells which express anti-idiotypic receptors. J Exp Med (1980) 3.21
The polymeric immunoglobulin receptor translocates pneumococci across human nasopharyngeal epithelial cells. Cell (2000) 3.19
Genetic control of specific immune suppression. II. H-2-linked dominant genetic control of immune suppression by the random copolymer L-glutamic acid50-L-tyrosine50 (GT). J Exp Med (1975) 3.17
Theta-bearing and complement-receptor lymphocytes are distinct populations of cells. Science (1971) 3.16
Regulation by the H-2 gene complex of macrophage-lymphoid cell interactions in secondary antibody responses in vitro. J Exp Med (1976) 3.10
Circumsporozoite proteins of malaria parasites contain a single immunodominant region with two or more identical epitopes. J Exp Med (1983) 3.07
Secondary antibody responses in haptenic systems: cell population selection by antigen. J Immunol (1967) 3.01
Genetic control of immune responses in vitro. 3. Tolerogenic properties of the terpolymer L-glutamic acid 60-L-alanine30-L-tyrosine10 (GAT) for spleen cells from nonresponder (H-2s and H-2q) mice. J Exp Med (1974) 3.01
Human C4-binding protein. II. Role in proteolysis of C4b by C3b-inactivator. J Exp Med (1978) 2.98
Linkage between the poly-L-lysine gene and the locus controlling the major histocompatibility antigens in strain 2 guinea pigs. Proc Natl Acad Sci U S A (1970) 2.89
Complementation of H-2-linked Ir genes in the mouse. Proc Natl Acad Sci U S A (1975) 2.88
Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids. J Exp Med (1987) 2.86
The basolateral domain of the hepatocyte plasma membrane bears receptors for the circumsporozoite protein of Plasmodium falciparum sporozoites. Cell (1992) 2.78
Genetic control of specific immune suppression. I. Experimental conditions for the stimulation of suppressor cells by the copolymer L-glutamic acid50-L-tyrosine50 (GT) in nonresponder BALB/c mice. J Exp Med (1975) 2.78
Monoclonal antibodies to circumsporozoite proteins identify the species of malaria parasite in infected mosquitoes. Nature (1982) 2.76
Modulation of the classical pathway C3 convertase by plasma proteins C4 binding protein and C3b inactivator. Proc Natl Acad Sci U S A (1979) 2.73
The histocompatibility-linked immune response genes. Adv Cancer Res (1975) 2.64
Suppressor cells and immunoregulation. Annu Rev Immunol (1984) 2.63
Malaria circumsporozoite protein binds to heparan sulfate proteoglycans associated with the surface membrane of hepatocytes. J Exp Med (1993) 2.60
Structure of the plasmodium knowlesi gene coding for the circumsporozoite protein. Cell (1983) 2.60
Human C4-binding protein. I. Isolation and characterization. J Exp Med (1978) 2.60
Genetic control of immune responsiveness to a glutamic acid, alanine, tyrosine copolymer in mice. I. Linkage of responsiveness to H-2 genotype. J Immunol (1971) 2.60
Signal for attachment of a phospholipid membrane anchor in decay accelerating factor. Science (1987) 2.59
Expression and function of the murine B7 antigen, the major costimulatory molecule expressed by peritoneal exudate cells. Proc Natl Acad Sci U S A (1992) 2.56
Carrier function in anti-hapten immune responses. II. Specific properties of carrier cells capable of enhancing anti-hapten antibody responses. J Exp Med (1970) 2.54
Mechanisms of regulation of cell-mediated immunity. II. Induction and suppression of delayed-type hypersensitivity to azobenzenearsonate-coupled syngeneic cells. J Immunol (1978) 2.52
Shared idiotypic determinants on antibodies and T-cell-derived suppressor factor specific for the random terpolymer L-glutamic acid60-L-alanine30-L-tyrosine10. J Exp Med (1979) 2.51
Cell surface immunoglobulin. IV. Distribution among thymocytes, bone mrrow cells, and their derived populations. J Exp Med (1972) 2.50
The distribution of antigenic and nonantigenic compounds within draining lymph nodes. Lab Invest (1966) 2.49
Circumsporozoite protein is required for development of malaria sporozoites in mosquitoes. Nature (1997) 2.49
Human lymphocytes bear membrane receptors for C3b and C3d. J Clin Invest (1973) 2.46
Antigen binding and capping by lymphocytes of genetic nonresponder mice. J Exp Med (1972) 2.46
Circumsporozoite proteins of malaria parasites. Cell (1985) 2.45
Cellular aspects of immunoglobulin A. Adv Immunol (1976) 2.44
Nobel laureates' letter to President Bush. Washington Post (2001) 2.43
Conservation of a gliding motility and cell invasion machinery in Apicomplexan parasites. J Cell Biol (1999) 2.43
Circumsporozoite protein of Plasmodium vivax: gene cloning and characterization of the immunodominant epitope. Science (1985) 2.41
Hapten-specific T-cell responses to 4-hydroxy-3-nitrophenyl acetyl. II. Demonstration of idiotypic determinants on suppressor T cells. J Exp Med (1979) 2.40
Research toward malaria vaccines. Science (1986) 2.40
The role of antigen-presenting B cells in T cell priming in vivo. Studies of B cell-deficient mice. J Immunol (1988) 2.39
Genetic control of specific immune suppression. IV. Responsiveness to the random copolymer L-glutamic acid50-L-tyrosine50 induced in BALB/c mice by cyclophosphamide. J Exp Med (1976) 2.39
Radioresistance of carrier-specific helper thymus-derived lymphocytes in mice. Proc Natl Acad Sci U S A (1972) 2.35
Antihapten antibody specificity and L chain type. J Exp Med (1967) 2.33